Middle East and Africa Neurological Biomarker Market to Grow at a CAGR of 11.0% to reach US$ 529.04 million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Middle East and Africa Neurological Biomarker Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Middle East and Africa Neurological Biomarker Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Rising incidences of neurological diseases
5.1.3 Rapid Developments in healthcare

5.2 Market Opportunities

5.2.1
5.2.2 Development of novel biomarkers
5.2.3 Integration of drug development and biomarkers
5.2.4 Focus on early detection and prevention

5.3 Future Trends

5.3.1
5.3.2 Advancement in biomarker discovery
5.3.3 increased focus on personalized medicines

5.4 Impact of Drivers and Restraints

6. Middle East and Africa Neurological Biomarker Market Regional Analysis

6.1 Middle East and Africa Neurological Biomarker Market Overview

6.2 Middle East and Africa Neurological Biomarker Market Revenue 2017-2027 (US$ Million)

6.3 Middle East and Africa Neurological Biomarker Market Forecast Analysis

7. Middle East and Africa Neurological Biomarker Market Analysis – by Product

7.1 Proteomics Biomarker

7.1.1 Overview
7.1.2 Proteomics Biomarker: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Genomics Biomarker

7.2.1 Overview
7.2.2 Genomics Biomarker: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Metabolomics Biomarker

7.3.1 Overview
7.3.2 Metabolomics Biomarker: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Imaging Biomarker

7.4.1 Overview
7.4.2 Imaging Biomarker: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

8. Middle East and Africa Neurological Biomarker Market Analysis – by Application

8.1 Alzheimer's Disease

8.1.1 Overview
8.1.2 Alzheimer's Disease: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Parkinson's Disease

8.2.1 Overview
8.2.2 Parkinson's Disease: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Schizophrenia

8.3.1 Overview
8.3.2 Schizophrenia: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Huntington's Disease

8.4.1 Overview
8.4.2 Huntington's Disease: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.5 Spinal Muscular Atrophy

8.5.1 Overview
8.5.2 Spinal Muscular Atrophy: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9. Middle East and Africa Neurological Biomarker Market Analysis – by End User

9.1 Pharmaceutical & Biotechnology Companies

9.1.1 Overview
9.1.2 Spinal Muscular Atrophy: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Clinical Diagnostics

9.2.1 Overview
9.2.2 Spinal Muscular Atrophy: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Research Organizations

9.3.1 Overview
9.3.2 Spinal Muscular Atrophy: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10. Middle East and Africa Neurological Biomarker Market – Middle East and Africa Analysis

10.1 Middle East and Africa

10.1.1 Middle East and Africa Neurological Biomarker Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 Middle East and Africa Neurological Biomarker Market – Revenue and Forecast Analysis – by Country
10.1.1.1 South Africa: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 South Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by Product
10.1.1.1.2 South Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by Application
10.1.1.1.3 South Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by End User

10.1.1.2 Saudi Arabia: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Saudi Arabia: Middle East and Africa Neurological Biomarker Market Breakdown, by Product
10.1.1.2.2 Saudi Arabia: Middle East and Africa Neurological Biomarker Market Breakdown, by Application
10.1.1.2.3 Saudi Arabia: Middle East and Africa Neurological Biomarker Market Breakdown, by End User

10.1.1.3 UAE: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 UAE: Middle East and Africa Neurological Biomarker Market Breakdown, by Product
10.1.1.3.2 UAE: Middle East and Africa Neurological Biomarker Market Breakdown, by Application
10.1.1.3.3 UAE: Middle East and Africa Neurological Biomarker Market Breakdown, by End User

10.1.1.4 Rest of Middle East and Africa: Middle East and Africa Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Rest of Middle East and Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by Product
10.1.1.4.2 Rest of Middle East and Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by Application
10.1.1.4.3 Rest of Middle East and Africa: Middle East and Africa Neurological Biomarker Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Middle East and Africa Neurological Biomarker Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Abbott

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bio-Rad Laboratories Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 QIAGEN

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Immunarray Pvt. Ltd.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Quest Diagnostics Incorporated

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Perkin Elmer, Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 MERCK KGaA

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights